Nutrients

Bifidobacterium animalis MN-Gup’s impact on blood sugar, gut bacteria, and their products in mice with type 2 diabetes

Updated

Abstract

A high-dose of MN-Gup significantly reduced fasting blood glucose levels in mice.

  • MN-Gup was administered at doses of 2 × 10^9 CFU/kg and 1 × 10^9 CFU/kg over 6 weeks.
  • Significant increases in , especially acetate, were observed in the MN-Gup group.
  • GLP-1 levels were also significantly elevated in the MN-Gup treated mice.
  • The treatment led to a decrease in insulin resistance as measured by the homeostasis model assessment (HOMA-IR).
  • The gut microbiota composition was altered, with increases in beneficial bacteria and decreases in potentially harmful ones.
  • Correlation analysis indicated a positive relationship between certain gut bacteria and GLP-1 levels.

Simplified

Key numbers

3.83 mmol/L
Decrease in Fasting Blood Glucose (FBG)
Difference in FBG levels between high-dose MN-Gup group and control group.
not provided
Increase in GLP-1 Levels
Comparison of GLP-1 levels in MN-Gup treated groups vs. control group.
not provided
Increase in Acetic Acid Levels
Comparison of acetic acid levels in MN-Gup treated groups vs. control group.

Full Text

What this is

  • This research investigates the effects of Bifidobacterium animalis subsp. lactis MN-Gup on glucose metabolism in type 2 diabetic mice.
  • The study evaluates how MN-Gup influences fasting blood glucose levels, insulin resistance, gut microbiota composition, and the secretion of () and GLP-1.
  • Findings indicate that MN-Gup has significant hypoglycemic effects and can modulate gut microbiota in a dose-dependent manner.

Essence

  • Bifidobacterium animalis subsp. lactis MN-Gup significantly reduces fasting blood glucose levels and insulin resistance in type 2 diabetic mice, while promoting beneficial gut microbiota and increasing and GLP-1 secretion.

Key takeaways

  • High-dose MN-Gup treatment significantly reduced fasting blood glucose (FBG) levels and homeostasis model assessment-insulin resistance (HOMA-IR) in type 2 diabetic mice compared to control groups.
  • The treatment increased levels of , particularly acetate, and (GLP-1), suggesting a mechanism for its hypoglycemic effects.
  • MN-Gup altered gut microbiota composition, increasing beneficial bacteria while decreasing potentially harmful strains, indicating a role in metabolic health.

Caveats

  • The study is limited to a mouse model, which may not fully replicate human diabetes physiology and treatment responses.
  • Further research is needed to explore the long-term effects and safety of MN-Gup in human subjects.

Definitions

  • Type 2 Diabetes Mellitus (T2DM): A metabolic disorder characterized by chronic hyperglycemia due to insulin resistance and impaired insulin secretion.
  • Short-Chain Fatty Acids (SCFAs): Fatty acids with fewer than six carbon atoms, produced by gut bacteria during the fermentation of dietary fibers, playing a role in gut health and metabolism.
  • Glucagon-Like Peptide-1 (GLP-1): An incretin hormone that enhances insulin secretion and lowers blood glucose levels, also involved in appetite regulation.

Simplified

Funding

Competing interests

Authors T.N., E.S., R.X., and S.L. were employed by the company Mengniu Hi-Tech Dairy Product Beijing Co., Ltd. They participated in this study. The primary role of the company was to provide necessary technical support for the research. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free